Info: Read More
  • ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Science | Nature | Cell | View More
    Natural Products
    CAS No. 58-63-9 Price $30 / 20mg
    Catalog No.CFN93249Purity>=98%
    Molecular Weight268.2Type of CompoundAlkaloids
    FormulaC10H12N4O5Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    Citing Use of our Products
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email:
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
    Size /Price /Stock 10 mM * 1 mL in DMSO / $8.9 / In-stock
    Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
    Our products had been exported to the following research institutions and universities, And still growing.
  • University of Helsinki (Finland)
  • Universit?t Basel (Switzerland)
  • Lodz University of Technology (Poland)
  • Universidad Miguel Hernández (Spain)
  • University of Beira Interior (Portugal)
  • Weizmann Institute of Science (Israel)
  • Amity University (India)
  • Donald Danforth Plant Science C... (USA)
  • Copenhagen University (Denmark)
  • Rio de Janeiro State University (Brazil)
  • Universidad de La Salle (Mexico)
  • More...
  • Package
    Featured Products

    Catalog No: CFN90232
    CAS No: 495-31-8
    Price: $100/20mg

    Catalog No: CFN92252
    CAS No: 510-22-5
    Price: $463/5mg

    Catalog No: CFN99106
    CAS No: 40957-83-3
    Price: $128/20mg

    Catalog No: CFN92154
    CAS No: 69618-96-8
    Price: $463/5mg
    Bruceine D

    Catalog No: CFN90771
    CAS No: 21499-66-1
    Price: $258/10mg

    Catalog No: CFN90536
    CAS No: 587-63-3
    Price: $318/20mg
    20R-Ginsenoside Rg2

    Catalog No: CFN90412
    CAS No: 80952-72-3
    Price: $298/20mg
    Related Screening Libraries
    Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
    10 mM * 1 mL in DMSO / Inquiry / In-stock
    Related Libraries
  • Anti-inflammatory Compound Library
  • Neuroprotection Compound Library
  • Immunomodulators Compound Library
  • Alkaloids Compound Library
  • SOD Inhibitor Library
  • PKC Inhibitor Library
  • PKA Inhibitor Library
  • NF-kB Inhibitor Library
  • Calcium Channel Inhibitor Library
  • AChR Inhibitor Library
  • Biological Activity
    Description: Inosine, an endogenous purine nucleoside, has immunomodulatory, neuroprotective, and analgesic properties.Inosine is a cardiotonic agent, can treat cardiac disorders.Inosine can to be capable of forming base pairs with Adenine HFN72-P, Cytosine HDR44-O or Uracil BTP40-U thus contributing to genetic code degeneracy by causing stable mispairings.
    Targets: NF-kB | SOD | PKA | AChR | PKC | Calcium Channel
    In vivo:
    JAMA Neurol. 2014 Feb;71(2):141-50.
    Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.[Pubmed: 24366103]
    Convergent biological, epidemiological, and clinical data identified urate elevation as a candidate strategy for slowing disability progression in Parkinson disease (PD). To determine the safety, tolerability, and urate-elevating capability of the urate precursor Inosine in early PD and to assess its suitability and potential design features for a disease-modification trial.
    The Safety of Urate Elevation in PD (SURE-PD) study, a randomized, double-blind, placebo-controlled, dose-ranging trial of Inosine, enrolled participants from 2009 to 2011 and followed them for up to 25 months at outpatient visits to 17 credentialed clinical study sites of the Parkinson Study Group across the United States. Seventy-five consenting adults (mean age, 62 years; 55% women) with early PD not yet requiring symptomatic treatment and a serum urate concentration less than 6 mg/dL (the approximate population median) were enrolled. Participants were randomized to 1 of 3 treatment arms: placebo or Inosine titrated to produce mild (6.1-7.0 mg/dL) or moderate (7.1-8.0 mg/dL) serum urate elevation using 500-mg capsules taken orally up to 2 capsules 3 times per day. They were followed for up to 24 months (median, 18 months) while receiving the study drug plus 1 washout month. The prespecified primary outcomes were absence of unacceptable serious adverse events (safety), continued treatment without adverse event requiring dose reduction (tolerability), and elevation of urate assessed serially in serum and once (at 3 months) in cerebrospinal fluid. RESULTS Serious adverse events (17), including infrequent cardiovascular events, occurred at the same or lower rates in the Inosine groups relative to placebo. No participant developed gout and 3 receiving Inosine developed symptomatic urolithiasis. Treatment was tolerated by 95% of participants at 6 months, and no participant withdrew because of an adverse event. Serum urate rose by 2.3 and 3.0 mg/dL in the 2 Inosine groups (P < .001 for each) vs placebo, and cerebrospinal fluid urate level was greater in both Inosine groups (P = .006 and <.001, respectively). Secondary analyses demonstrated nonfutility of Inosine treatment for slowing disability.
    Inosine was generally safe, tolerable, and effective in raising serum and cerebrospinal fluid urate levels in early PD. The findings support advancing to more definitive development of Inosine as a potential disease-modifying therapy for PD.
    Brain Res. 2014 Mar 25;1555:78-88.
    Inosine improves functional recovery after experimental traumatic brain injury.[Pubmed: 24502983]
    Despite years of research, no effective therapy is yet available for the treatment of traumatic brain injury (TBI). The most prevalent and debilitating features in survivors of TBI are cognitive deficits and motor dysfunction. A potential therapeutic method for improving the function of patients following TBI would be to restore, at least in part, plasticity to the CNS in a controlled way that would allow for the formation of compensatory circuits. Inosine, a naturally occurring purine nucleoside, has been shown to promote axon collateral growth in the corticospinal tract (CST) following stroke and focal TBI.
    In the present study, we investigated the effects of Inosine on motor and cognitive deficits, CST sprouting, and expression of synaptic proteins in an experimental model of closed head injury (CHI). Treatment with Inosine (100 mg/kg i.p. at 1, 24 and 48 h following CHI) improved outcome after TBI, significantly decreasing the neurological severity score (NSS, p<0.04 vs. saline), an aggregate measure of performance on several tasks. It improved non-spatial cognitive performance (object recognition, p<0.016 vs. saline) but had little effect on sensorimotor coordination (rotarod) and spatial cognitive functions (Y-maze). Inosine did not affect CST sprouting in the lumbar spinal cord but did restore levels of the growth-associated protein GAP-43 in the hippocampus, though not in the cerebral cortex.
    Our results suggest that Inosine may improve functional outcome after TBI.
    Transplant Proc. 2014 Jan-Feb;46(1):40-5.
    Preconditioning with gabexate is superior to inosine for ameliorating acute renal ischemia-reperfusion injury in rats.[Pubmed: 24507023]
    The objective of this study was to compare the protease inhibitor gabexate with widely used Inosine for reducing renal ischemia-reperfusion injury.
    A total of 48 rats were divided into 4 groups of 12 and administered gabexate, Inosine, normal saline (NS), or nothing by injection through the vena dorsalis of the penis. Then all rats were subjected to right nephrectomy and 30-minute warm ischemia of the left kidney. At 24 and 48 hours after reperfusion, blood samples were collected from the inferior vena cava and serum creatinine (SCr) was assayed. Left kidney tissue was homogenized and used to assay malondialdehyde (MDA) and superoxide dismutase (SOD). The tissue was also analyzed using hematoxylin-eosin (HE) staining, TUNEL staining, and NF-κB immunohistochemistry. SCr level decreased after reperfusion more in the gabexate group than in the other groups. Reperfused kidney tissue in the gabexate group showed lower MDA levels but higher SOD activity than did tissue in the Inosine and saline groups, as well as lower pathology scores based on HE staining, lower necrosis index, and lower levels of NF-κB expression (all P < .05). Tissue in the Inosine and saline groups showed similar necrosis index and NF-κB expression (P > .05).
    Preconditioning with gabexate is superior to preconditioning with Inosine for ameliorating rat renal ischemia-reperfusion injury. Future studies are needed to verify the effects of gabexate in the clinic, especially for kidney transplantation.
    Inosine Description
    Source: The herbs of Beta vulgaris.
    Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to:

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN95046
    CAS No: 56939-52-7
    Price: $333/5mg
    Angelol H

    Catalog No: CFN91925
    CAS No: 83247-73-8
    Price: $338/5 mg
    Methyl neochebulinate

    Catalog No: CFN95201
    CAS No: 1236310-34-1
    Price: $398/5mg

    Catalog No: CFN97737
    CAS No: 471271-55-3
    Price: $333/5mg
    Ganoderic acid D

    Catalog No: CFN90292
    CAS No: 108340-60-9
    Price: $338/10mg
    (-)-Epiafzelechin 3-O-gallate

    Catalog No: CFN95081
    CAS No: 108907-43-3
    Price: $388/5mg
    Leachianol G

    Catalog No: CFN95146
    CAS No: 164204-62-0
    Price: $368/5mg
    Gancaonin N

    Catalog No: CFN95066
    CAS No: 129145-52-4
    Price: $463/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.7286 mL 18.6428 mL 37.2856 mL 74.5712 mL 93.214 mL
    5 mM 0.7457 mL 3.7286 mL 7.4571 mL 14.9142 mL 18.6428 mL
    10 mM 0.3729 mL 1.8643 mL 3.7286 mL 7.4571 mL 9.3214 mL
    50 mM 0.0746 mL 0.3729 mL 0.7457 mL 1.4914 mL 1.8643 mL
    100 mM 0.0373 mL 0.1864 mL 0.3729 mL 0.7457 mL 0.9321 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Kinase Assay:
    Br J Pharmacol. 2013 Aug;169(8):1810-23.
    Inosine induces presynaptic inhibition of acetylcholine release by activation of A3 adenosine receptors at the mouse neuromuscular junction.[Pubmed: 23731236]
    The role of Inosine at the mammalian neuromuscular junction (NMJ) has not been clearly defined. Moreover, Inosine was classically considered to be the inactive metabolite of adenosine. Hence, we investigated the effect of Inosine on spontaneous and evoked ACh release, the mechanism underlying its modulatory action and the receptor type and signal transduction pathway involved.
    End-plate potentials (EPPs) and miniature end-plate potentials (MEPPs) were recorded from the mouse phrenic-nerve diaphragm preparations using conventional intracellular electrophysiological techniques. Inosine (100 μM) reduced MEPP frequency and the amplitude and quantal content of EPPs; effects inhibited by the selective A3 receptor antagonist MRS-1191. Immunohistochemical assays confirmed the presence of A3 receptors at mammalian NMJ. The voltage-gated calcium channel (VGCC) blocker Cd(2+) , the removal of extracellular Ca(2+) and the L-type and P/Q-type VGCC antagonists, nitrendipine and ω-agatoxin IVA, respectively, all prevented Inosine-induced inhibition. In the absence of endogenous adenosine, Inosine decreased the hypertonic response. The effects of Inosine on ACh release were prevented by the Gi/o protein inhibitor N-ethylmaleimide, PKC antagonist chelerytrine and calmodulin antagonist W-7, but not by PKA antagonists, H-89 and KT-5720, or the inhibitor of CaMKII KN-62.
    Our results suggest that, at motor nerve terminals, Inosine induces presynaptic inhibition of spontaneous and evoked ACh release by activating A3 receptors through a mechanism that involves L-type and P/Q-type VGCCs and the secretory machinery downstream of calcium influx. A3 receptors appear to be coupled to Gi/o protein. PKC and calmodulin may be involved in these effects of Inosine.
    Animal Research:
    Sci Rep. 2014 Feb 26;4:4199.
    Oral administration of inosine produces antidepressant-like effects in mice.[Pubmed: 24569499]
    Inosine, a breakdown product of adenosine, has recently been shown to exert immunomodulatory and neuroprotective effects.
    We show here that the oral administration of Inosine has antidepressant-like effects in two animal models. Inosine significantly enhanced neurite outgrowth and viability of primary cultured neocortical neurons, which was suppressed by adenosine A1 and A2A receptor agonists. Oral administration of Inosine to mice transiently increased its concentration in the brain and enhanced neuronal proliferation in the dentate gyrus, accompanied by phosphorylation of mitogen-activated protein kinase and increase in transcript level of brain-derived neurotrophic factor. In stress models, oral Inosine prevented an increase in immobility time in forced swim test after chronically unexpected stress and mitigated a reduction in sucrose preference after chronic social defeat stress.
    These results indicate that oral administration of Inosine has the potential to prevent depressive disorder via adenosine receptors.